

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## OPTimal TIMing of antenatal CORTicosteroid administration in pregnancies complicated by early-onset fetal growth REstriction (OPTICORE): study protocol of a multicentre, retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070729
Article Type:	Protocol
Date Submitted by the Author:	02-Dec-2022
Complete List of Authors:	<p>van de Meent, Mette; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Kleuskens, D.; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Ganzevoort, Wessel; Amsterdam University Medical Centres, Department of Obstetrics and Gynaecology          Gordijn, Sanne; University Medical Centre Groningen, Department of Obstetrics and Gynaecology          Kooi, E.; University Medical Centre Groningen, Department of Neonatology          Onland, Wes; Amsterdam University Medical Centres, Department of Paediatrics          van Rijn, Bas; Erasmus MC, Department of Obstetrics and Gynaecology          Duvetkot, J.J.; Erasmus MC, Department of Obstetrics and Gynaecology          Kornelisse, René; Erasmus MC Sophia, Department of Paediatrics          Al-Nasiry, Salwan; Maastricht UMC+, Department of Obstetrics and Gynaecology          Jellema, R.; Maastricht UMC+, Department of Neonatology          Knol, H. ; Isala Zwolle, Department of Obstetrics and Gynaecology          Manten, G.; Isala Zwolle, Department of Obstetrics and Gynaecology          Mulder-deTollenaere, S. ; Isala Zwolle, Department of Neonatology          Derks, J. ; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Groenendaal , Floris ; University Medical Centre Utrecht, Department of Neonatology          Bekker, Mireille; UMC Utrecht, Department of Obstetrics and Gynaecology          Schuit, Ewoud; Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht          Lely, Titia; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Kooiman, J.; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology</p>
Keywords:	NEONATOLOGY, EPIDEMIOLOGY, OBSTETRICS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# OPTimal Timing of antenatal COrticosteroid administration in pregnancies complicated by early-onset fetal growth REstriction (OPTICORE): study protocol of a multicentre, retrospective cohort study

M. van de Meent, MD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, the Netherlands

D. G. Kleuskens, BSc, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

W. Ganzevoort, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands

S. J. Gordijn, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, University Medical Center Groningen, the Netherlands

E. M. W. Kooi, MD, PhD, Associate Professor, department of Neonatology, University Medical Center Groningen, the Netherlands

W. Onland, MD, PhD, department of Neonatology, Amsterdam University Medical Center, location AMC, Amsterdam and Amsterdam Reproduction & Development, Amsterdam, the Netherlands

B. B. van Rijn, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, the Netherlands

J. J. Duvekot, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, the Netherlands

R. F. Kornelisse, MD, PhD, department of Neonatology, Erasmus Medical Center, Rotterdam, the Netherlands

S. Al-Nasiry, MD, PhD, department of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, the Netherlands

R. Jellema, MD, PhD, department of Neonatology, Maastricht University Medical Center, Maastricht, the Netherlands

H. M. Knol, MD, PhD, department of Obstetrics and Gynaecology, Isala Zwolle, the Netherlands

G. T. R. Manten, MD, PhD, department of Obstetrics and Gynaecology, Isala Zwolle, the Netherlands

S. M. Mulder-de Tollenaer, MD, PhD, department of Neonatology, Isala Zwolle, the Netherlands

J. B. Derks, MD, PhD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

F. Groenendaal, MD, PhD, Associate Professor, department of Neonatology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

M. N. Bekker, MD, PhD, Full Professor, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

E. Schuit, PhD, Assistant Professor, University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands

A. T. Lely, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

J. Kooiman, MD, PhD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Lundlaan 6, 3584 EA, Utrecht, [j.kooiman@umctrecht.nl](mailto:j.kooiman@umctrecht.nl)\*

\*Corresponding author

Word count: 2886

## ABSTRACT

### Introduction

Early-onset fetal growth restriction (FGR) requires timely and therefore often preterm delivery to prevent fetal hypoxia leading to stillbirth or neurologic impairment. To reduce neonatal morbidity and mortality following this preterm birth, antenatal corticosteroids (CCS) are administered. The efficacy of CCS is likely to be highest when delivery takes place within one to seven days after the last dose. Optimal timing of CCS administration is challenging in the setting of early-onset FGR, as the exact onset and course of fetal hypoxia is unpredictable. Of note, international guidelines do not provide directives on this topic. In the Netherlands, two timing strategies are commonly practiced: administration of CCS when the umbilical artery A) shows a pulsatility index above the 95<sup>th</sup> centile; B) shows absent or reversed end-diastolic velocity (a more progressed disease state). This study aims to 1) use practice variation to compare these two CCS timing strategies in early-onset FGR on fetal and neonatal outcomes, and 2) develop a dynamic tool to predict the time interval in days until delivery, which could be used as an additional timing strategy for antenatal CCS treatment in early-onset FGR.

### Methods and analysis

A multicentre, retrospective cohort study will be performed including patients treated between 2012 and 2021 in six of the nine tertiary perinatal hospitals in the Netherlands (estimated sample size n=1800). Primary outcome for the comparison of the two CCS timing strategies is a composite of perinatal, neonatal and in-hospital mortality. Secondary outcomes are in line with the COSGROVE core outcome set for FGR including long-term follow-up. For the dynamic prediction tool, the primary endpoint is defined as days until birth.

### **Ethics and dissemination**

The need for ethical approval was waived by the Ethics Committee of the University Medical Center Utrecht (METC NedMec, registration number 22/613).

### **Trial registration**

ClinicalTrials.gov registration number: NCT05606497.

### **Strengths and limitations of this study**

- This large cohort study will provide important information on the ideal momentum for antenatal CCS treatment in pregnancies complicated by early-onset fetal growth restriction (FGR). With that, we aim to reduce neonatal morbidity and mortality for future FGR pregnancies.
- Practice variation will be used to study two commonly practiced timing strategies of antenatal CCS therapy in early-onset FGR.
- Second, a dynamic prediction tool will be developed to forecast the time interval until birth, a novel technique in prediction research.
- A possible limitation of our observational study is reflected by other differences in obstetric and neonatal routine care (other than antenatal CCS timing strategies) that might influence study outcome measures.

## BACKGROUND

Early-onset fetal growth restriction (FGR) is defined as failure of a fetus to meet its growth potential, with its detection before 32 weeks of pregnancy. Early-onset FGR occurs in approximately 0.5-1% of all pregnancies and is a notable cause of stillbirth (2%), neonatal morbidity (24%) and mortality (8-19%) (1-5). In developed countries, early-onset FGR is most commonly caused by placental dysfunction leading to unmet fetal metabolic and gaseous demands (6,7). In a prolonged and increasing hypoxic state, the anticipated risks of stillbirth rise. Active fetal surveillance of early-onset FGR pregnancies is therefore warranted and consists of ultrasound (fetal Doppler sonography) and analyses of the fetal heart rate pattern (cardiotocography) to detect critical fetal hypoxia and instigate timely, most often preterm, delivery. Alternatively, maternal health issues can warrant for pre-term termination of pregnancy as early-onset FGR frequently coincides with (pre-)eclampsia (8).

Antenatal corticosteroids (CCS) lower the risks of neonatal morbidity and mortality following spontaneous preterm birth (9,10). Literature suggests that antenatal CCS treatment may be most beneficial in reducing adverse neonatal outcome when a completed course of CCS (i.e. two doses of betamethasone or dexamethasone at an 24 hours interval) is administered one to seven days prior birth (adjusted odds ratio 1.46, 95% confidence interval (CI) 1.20-1.77 as compared to an time span longer than 7 days prior to birth) (11). Although the clinical benefit and possible harms of antenatal CCS therapy are subject of debate in early-onset FGR, it is one of the very few antenatal treatments that can possibly improve neonatal health. Repeated courses of CCS should be avoided, as they have been associated with decreased birthweight, length, head circumference and higher rates of cerebral palsy (12,13). Therefore, adequate timing of CCS administration is likely to be important, also in the setting of early-onset FGR pregnancies when preterm birth is anticipated.

1  
2  
3 There is consensus that repetitive decelerations on the cardiotocography registration  
4 reflect fetal distress and an increased risk of fetal death (13). They are thus an important trigger  
5  
6  
7  
8 to initiate birth. Unfortunately, it is difficult to predict when these repetitive decelerations will  
9  
10 occur during the period of active fetal surveillance, which makes it challenging to administer  
11  
12  
13 CCS within the ideal timeframe of 7 days prior to birth. International guidelines do not provide  
14  
15 directives regarding the timing of CCS treatment in early-onset FGR (1,14–16). In the  
16  
17 Netherlands, two timing strategies regarding antenatal CCS administration in early-onset FGR  
18  
19 are currently being practiced (Figure 1 (17)):

- 20  
21  
22  
23 - Strategy "A": administration of CCS when the pulsatility index (PI) of the umbilical artery  
24  
25 (UA) becomes abnormal (i.e. > 95th percentile), irrespective of its end-diastolic  
26  
27 waveform.
- 28  
29  
30 - Strategy "B": administration of CCS when absent or reversed end-diastolic velocity of  
31  
32 the UA is detected, thus in a more progressed disease state as compared to strategy A.  
33

34  
35 This study aims to compare these two timing strategies regarding CCS administration in early-  
36  
37 onset FGR on the composite outcome of perinatal, neonatal and in-hospital mortality. In  
38  
39 addition, we aim to develop a dynamic, prediction tool to regularly assess the time interval  
40  
41 until birth during the period of active fetal surveillance. Ultimately, the use of such a dynamic  
42  
43 risk tool could be used as an additional timing strategy for CCS treatment in early-onset FGR  
44  
45 to improve neonatal outcome.  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **METHODS**

### 55 56 57 **Objective** 58 59 60



1  
2  
3 The primary objective of this study is to optimize the timing of antenatal CCS administration in  
4 pregnancies complicated by early-onset FGR. With that, we aim to reduce perinatal, neonatal  
5 and in-hospital mortality. To do so, we will 1) compare two timing strategies regarding CCS  
6 administration in early-onset FGR; 2) develop a dynamic, prediction tool with the outcome  
7 "days until birth". This dynamic prediction model could serve as an additional strategy to plan  
8 for CCS treatment.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Study design and setting**

21  
22 A multicentre, retrospective cohort study will be performed. Patients will be included from six  
23 tertiary teaching hospitals in the Netherlands if diagnosed with early-onset FGR between 2012  
24 and 2021. Neonates were actively managed at 24 weeks since 2010 in the Netherlands.  
25 Therefore, and considering the learning curve neonatologists experienced in the first two years  
26 of this new policy, patients will be included from 2012 onwards. Each CCS timing strategy (as  
27 described in the introduction) is practiced by three of six participating hospitals. By using this  
28 practice variation between hospitals, our cohort study mimics the design of a cluster  
29 randomized controlled trial (RCT). This study protocol was submitted to the Ethics Committee  
30 of the University Medical Center Utrecht (METC NedMec, registration number 22/613), which  
31 confirmed that the Medical Research Involving Human Subjects Act (WMO) did not apply to  
32 this study. Therefore, an official approval was not required under the WMO (18). In addition,  
33 the need for informed consent was waived as an exception was made in accordance with the  
34 General Data Protection Regulation (19). Patients or the public were not involved in the design,  
35 conduct, reporting or dissemination plans of this study.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Study population**

To be eligible for inclusion, a patient must meet all of the following criteria: 1) Early-onset FGR in accordance with the consensus-based definition of Gordijn *et al.* (20); 2) Singleton pregnancy; 3) Age  $\geq$  18 years; 4) Installed active, neonatal management after counselling (thus having an indication for CCS administration in case of birth < 34 weeks of gestational age). Exclusion criteria are 1) Multiple pregnancies; 2) Fetal congenital abnormalities or antenatal diagnosed genetic disorders; 3) Patients who stated that their patient or offspring data may not be used for scientific research.

### Data collection

Patients will be identified using parturition books. Data will be captured in a CASTOR electronic case report form, a Good Clinical Practice compliant Electronic Data Capture system (21).

Medical records will be scrutinized for patient characteristics of mothers as well as the neonates. Neonates are often transferred to a level II referral hospital after being treated in the level III NICU of the participating hospitals. To complete information on neonatal study outcomes, admission or discharge letters of these patient transfers will be traced to ensure complete follow-up assessment. In addition, follow-up on our primary outcome is safeguarded by a national registration on pregnancy outcomes (PERIDOS). Information on neurodevelopment will be obtained from follow-up assessments in the participating perinatal centers or from letters of the local paediatricians. All variables and outcomes that will be collected are summarized in Table 1.

**Table 1.** Maternal and neonatal patient characteristics

Maternal characteristics	Pregnancy characteristics	Neonatal characteristics
Age	Gestational age at time of diagnosis	Sex
Ethnic background	Gravidity	Gestational age at birth
Smoking status	Parity	Birth weight
Drug use	Time between corticosteroid administration and birth (days)	Birth weight centile (Hoftiezer)
Body Mass Index	Mode of delivery (caesarean or vaginal)	Apgar scores at 5 minutes

Transfer to other perinatal centers before delivery	<u>Pre-existent disorders</u> Chronic kidney disease; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Antiphospholipid Syndrome; Diabetes; Chronic Hypertension; Other medical disease affecting maternal or neonatal outcome	Arterial and venous pH with base excess
	<u>Obstetric history</u> Previous pregnancy affected by fetal growth restriction, pre-eclampsia, (iatrogenic) preterm birth or diabetes gravidarum.	<u>Mechanical ventilation</u> Need for mechanical ventilation during admission, whether this was <72 hours after birth and the duration (days).
	<u>Hypertensive disorders of pregnancy</u> Pregnancy-Induced Hypertension; Pre-eclampsia	Duration supplemental oxygen during admission
	<u>Ultrasound-based markers (of each performed ultrasound examination)</u> Pulsatility index of umbilical artery; End-diastolic velocity waveform umbilical artery; Estimated fetal weight; Pulsatility index of middle cerebral artery; Cerebroplacental Ratio; Pulsatility index of veins ductus venosus; Atrial systolic velocity of ductus venosus; Presence of echodense fetal bowel	Perinatal, neonatal and in-hospital death
	<u>Cardiotocography registration</u> Short-term variation (if available); Presence of repetitive decelerations	<u>Adverse outcome measures</u> Respiratory Distress Syndrome; Necrotizing Enterocolitis $\geq 2$ according to the Bell's stages; Bronchopulmonary Dysplasia, moderate and severe; Intraventricular Hemorrhage grade 3, venous infarction, posthemorrhagic ventricular dilatation; Cystic Periventricular Leukomalacia; Retinopathy of prematurity with plus disease to which treatment is needed ; Early and delayed neonatal sepsis, culture-proven or clinically suspected; Persistent pulmonary hypertension of the newborn
	<u>Other pregnancy-related disorders</u> Pregnancy cholestasis; Gestational diabetes	Long-term follow-up
	Fetal death	

## Outcomes

### *Objective 1) Comparison main timing strategies of CCS in early-onset FGR*

Primary endpoint is defined as a composite of perinatal, neonatal and in-hospital mortality.

Follow-up for this endpoint is defined as time between diagnosis of early-onset FGR and perinatal, neonatal and in-hospital mortality, or to discharge to home. Secondary outcomes for this study objective are defined in accordance with the Core Outcome Set for FGR (COSGROVE)-study supplemented with other relevant maternal outcomes (22), see Supplementary file 1. Follow-up on offspring outcomes is extended until 2-years of corrected

1  
2  
3 age. Outcome measures regarding long-term follow up will be collected if available (i.e. for  
4  
5 children born before 30 weeks gestational age, for children born after a longer pregnancy  
6  
7 duration follow-up management varies between clinics). Follow-up on secondary maternal  
8  
9 outcomes ends after six weeks post-partum (Figure 2 (17)).  
10  
11  
12  
13  
14

15 *Objective 2) Development of a dynamic prediction tool of days until birth*

16  
17 We will develop a dynamic prediction model to regularly assess the time interval until birth  
18  
19 during the period of active fetal surveillance. Such a dynamic prediction model could warrant  
20  
21 physicians on the upcoming pre-term delivery and can therefore serve as a trigger for CCS  
22  
23 administration. Traditionally, prognostic models are based on 'statistic' information, not  
24  
25 considering the vast amount of new information that becomes available on a daily basis. To  
26  
27 better align with clinical care, dynamic prediction could be used, a novel technique in the risk  
28  
29 assessment research field (23). Daily updates can be generated on the outcome of "days until  
30  
31 birth" by adding new information about maternal or fetal health, e.g. retrieved by  
32  
33 ultrasonography and CTG-registration routinely used in FGR pregnancies, to the dynamic  
34  
35 equation. This provides the physician with an up-to-date time interval assessment.  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **Statistical analyses**

46  
47 *Objective 1) Comparison main timing strategies of CCS in early-onset FGR*

48  
49 As our study design mimics a cluster-RCT, we will align our statistical analysis with the methods  
50  
51 practiced by such trials. Intra-cluster correlation should thus be considered. Primary and  
52  
53 secondary outcomes will be compared between the two timing strategies by use of the practice  
54  
55 variation between the participating centers using a multivariable, mixed-effects model, taking  
56  
57 hierarchy of the data into account. Important differences in routine care between the  
58  
59  
60

1  
2  
3 participating centers, other than the timing strategy, and between participants across the  
4  
5 timing strategies are considered to be important confounding variables, and will be adjusted  
6  
7 for in the analyses. These differences in routine care will be identified by studying local,  
8  
9 management protocols and by scheduling research meetings to discuss routine care in the  
10  
11 participating centers. Adjusted odds ratios with 95% confidence intervals will be calculated for  
12  
13 dichotomous outcome measures and mean with standard deviations will be calculated for  
14  
15 continuous outcome measures (and median with interquartile range for continuous non-  
16  
17 parametric outcomes). Timing strategy "A" will be held as reference group. For secondary  
18  
19 outcome measures similar analyses will be performed. Exploratory subgroup analyses will be  
20  
21 performed based on gestational age at birth (below versus above 34 weeks). Heterogeneous  
22  
23 treatment effects will be assessed by introducing an interaction term between the subgroup  
24  
25 variable and the CCS treatment timing strategy to the mixed-effects model for the primary  
26  
27 outcome. A formal test of interaction will be performed. Afterwards, the primary analysis will  
28  
29 be repeated within each stratum of the subgroup.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 *Objective 2) Development of a dynamic prediction tool of days until birth*

41  
42  
43 **Table 2.** Candidate predictors dynamic, prediction tool

Fetal	Maternal
Estimated fetal weight	Presence of hypertensive disorders of pregnancy
Gestational age	Use of anti-hypertensive drugs
Pulsatility index umbilical artery	Use of intravenous anti-hypertensive medication
Pulsatility index cerebral middle artery	Use of magnesium sulphate
Cerebroplacental ratio	Number of hypertensive crises
Pulsatility index of veins ductus venosus	Presence of lung edema
Absence of interval growth	Progression of organ dysfunction
Repetitive decelerations on CTG	
Short-term variability	
Subjective fetal movements	

44 To allow dynamic prediction,  
45 information known at baseline as  
46 well as subsequent clinical and  
47 ultrasonographic information that  
48 becomes available will be used in  
49 a proportional baselines  
50 landmark supermodel, with days  
51 until birth as the outcome (24).  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Candidate predictors were selected based on literature and clinical practice, summarized in  
4  
5 Table 2. For these candidate predictors, repeated measures will be gathered on the day of every  
6  
7 follow-up ultrasonography (i.e. once or twice a week). The final set of predictors will be selected  
8  
9 using backward stepwise elimination based on the Akaike Information Criterion. Internal  
10  
11 validation using bootstrapping and subsequent shrinkage will be performed to account for  
12  
13 potential overfitting. Model performance will be reported by assessing discrimination based  
14  
15 on the c-statistic, and calibration both visually using calibration plots and quantitatively using  
16  
17 the calibration-in-the-large and calibration slope. The c-statistic, calibration-in-the-large, and  
18  
19 calibration slope will be determined at each time point, and we will report this series of model  
20  
21 performances in a graph. Statistical analyses will be conducted using the latest version of R at  
22  
23 the time of analysis (current version 4.0.3.1.32) (25).  
24  
25  
26  
27  
28  
29  
30  
31

### 32 **Sample size calculation**

#### 33 *Objective 1) Comparison main timing strategies of CCS in early-onset FGR*

34  
35 We performed a power calculation based on the fact that our study design mimics a cluster-  
36  
37 RCT. As such, intra-cluster correlation of study outcomes needs to be considered when  
38  
39 performing sample size calculations using an intra-cluster correlation coefficient. We used  
40  
41 three clusters (i.e. hospitals) per CCS timing strategy, an expected incidence of 6.8% on our  
42  
43 primary outcome (based on the TRUFFLE trial) and an intra-cluster correlation coefficient  
44  
45 varying between 0.001-0.0091 for calculations (3,26). Including patient data from six  
46  
47 participating hospitals will allow us to detect a range in minimal difference on the primary  
48  
49 outcome of 1.7-4.6% (3,27). We expect that inclusion in six hospitals over a ten year time period  
50  
51 will result in a total sample of approximately 1800 patients.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *Objective 2) Development of a dynamic prediction tool of days until birth*  
4

5  
6 Currently, no formal sample size calculation requirements are available for dynamic prediction  
7  
8 model development. We will use the same sample size as for objective 1. Number of candidate  
9  
10 predictors will be based on Riley *et al.*, using a margin of error of 5%, expected shrinkage factor  
11  
12 of 0.9, and Cox-Snell R squared statistic of 0.099 (28).  
13  
14  
15

16  
17 **DISCUSSION**  
18

19 The OPTimal TIMing of antenatal COrticosteroids in early-onset fetal growth REstriction  
20 (OPTICORE)-study will provide a large cohort of early-onset FGR pregnancies, including patient  
21  
22 data of six participating hospitals in the Netherlands. The results derived from this study will  
23  
24 likely provide the clinician with guidance on the optimal time window for antenatal CCS  
25  
26 administration in this patient population. With that, we aim to improve the neonatal and overall  
27  
28 outcome for future early-onset FGR pregnancies.  
29  
30  
31  
32

33  
34 There is an abundance of literature about the efficacy of antenatal CCS administration  
35  
36 in women undergoing spontaneous preterm labour. Optimal timing of antenatal CCS  
37  
38 administration – with a completed course between one and seven days before delivery – shows  
39  
40 the largest risk reduction for infant mortality compared to no administration of antenatal CCS  
41  
42 (adjusted risk ratio 0.5, 95%CI 0.4-0.6) versus a time interval of more than seven days till birth  
43  
44 (adjusted risk ratio 0.7, 95%CI 0.6-0.9) (29). Similar results were found for the outcome of severe  
45  
46 neonatal brain injury and a composite outcome measure of mortality and/or severe neonatal  
47  
48 morbidity (29). However, strong evidence for the efficacy (or the absence of it) of antenatal CCS  
49  
50 treatment in the setting of early-onset FGR is lacking, as no subgroup analysis has been  
51  
52 performed on this specific population in previously performed RCTs (9). The relative hypoxic  
53  
54 and starved intra-uterine environment in early-onset FGR likely results in higher levels of fetal  
55  
56  
57  
58  
59  
60

1  
2  
3 endogenous corticosteroids. It remains uncertain whether antenatal CCS administration on top  
4  
5 of this increased fetal endogenous corticosteroid release is still of benefit (30). Nevertheless,  
6  
7 international guidelines on FGR advise to administer antenatal CCS in pregnancies at risk for  
8  
9 preterm birth.  
10  
11

12  
13 Adequate timing of CCS treatment is challenging as the time interval until delivery in  
14  
15 early-onset FGR pregnancies is difficult to forecast. Risks of stillbirth or neurological  
16  
17 impairment due to acute (on top of chronic) hypoxia have to be balanced against the risks of  
18  
19 neonatal morbidity and mortality due to prematurity. The landmark TRUFFLE and GRIT trials,  
20  
21 that assessed CTG and ultrasound parameters as triggers for timely delivery in FGR  
22  
23 pregnancies, have not resulted in clear uniform recommendations on how to time delivery  
24  
25 (3,31). In an observational study, Hecher *et al.* described the time sequence pattern in the  
26  
27 development of abnormalities in fetal Doppler patterns and CTG-registration, the latter  
28  
29 ultimately demanding delivery. They included 110 cases of FGR in a prospective, longitudinal  
30  
31 study. However, not all pregnancies complicated by early-onset FGR follow this pattern in daily  
32  
33 practice and especially the time line of changes in Doppler pattern until delivery varies between  
34  
35 patients. Additionally, maternal factors (such as concomitant (pre-)eclampsia warranting birth)  
36  
37 were ignored in the time sequence monitoring-management summary. Consequently, due to  
38  
39 the heterogeneity in time sequence patterns and the continuous trade-off between fetal,  
40  
41 neonatal, and maternal health, the optimal timing of delivery remains a major clinical challenge  
42  
43 in early-onset FGR.  
44  
45  
46  
47  
48  
49

50  
51 The ideal design to compare the two strategies for CCS administration would be a RCT.  
52  
53 However, a sample size for such a trial would be challenging given the low incidence of both  
54  
55 early onset-FGR and our primary outcome. We thus chose to perform a retrospective cohort  
56  
57 study over a timespan of a decade, using practice variation as an instrument to mimic a cluster-  
58  
59  
60



1  
2  
3 RCT. Follow-up on our primary outcome is safeguarded by a national registration on pregnancy  
4  
5 outcomes (PERIDOS). However, achieving complete follow-up on the various other neonatal  
6  
7 outcomes can be challenging, especially for the secondary outcome of bronchopulmonary  
8  
9 dysplasia, as neonates will be transferred to a level II referral hospital when they are well  
10  
11 enough to be discharged from the neonatal intensive care unit. To overcome this limitation,  
12  
13 we will use discharge letters from the level II referral hospitals to complete follow-up  
14  
15 information. Another challenge will be the patient transfers between tertiary care centers for  
16  
17 delivery (e.g. because of unavailability of care on the neonatal intensive care unit), as patients  
18  
19 in our study are allocated to the center where they give birth while their CCS strategy was  
20  
21 installed elsewhere. This results in cross-over between the treatment strategies in our  
22  
23 intention-to-treat analysis. Other differences in obstetric and neonatal routine care (other than  
24  
25 antenatal CCS timing strategies) might influence the primary and secondary outcome measures  
26  
27 regarding perinatal and neonatal mortality and morbidity. Analyses will be corrected for  
28  
29 confounding factors, yet residual confounding could remain an issue of our study design.  
30  
31  
32  
33  
34  
35  
36

37 Strengths of this study comprise the large sample size that will be included in the study,  
38  
39 the use of a consensus-based definition of early-onset FGR and the collection of outcome  
40  
41 measures according to the COSGROVE-study with core outcomes for FGR (22). Also, we will  
42  
43 use a novel and promising technique in prediction research, namely dynamic prediction (23,24).  
44  
45 A multivariable and dynamic tool for initiation of CCS therapy might very well be superior to  
46  
47 the use of a single-variable trigger (as used by strategies A and B) in terms of predicting the  
48  
49 interval until birth. We will use this technique to develop an additional strategy to define the  
50  
51 optimal time window for antenatal CCS therapy.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In summary, this large cohort of early-onset FGR pregnancies will provide important  
4 insights in the timing of antenatal CCS in pregnancies complicated by early-onset FGR. With  
5  
6 that, we aim to reduce perinatal, neonatal and in-hospital mortality.  
7  
8  
9

## 10 11 12 **LIST OF ABBREVIATIONS**

13  
14  
15 CCS – Corticosteroids

16  
17 CI – Confidence Interval

18  
19 COSGROVE - Core Outcome Set for Fetal Growth Restriction

20  
21 FGR – Fetal Growth Restriction

22  
23 PI – Pulsatility Index

24  
25 RCT – Randomized Controlled Trial

26  
27 UA – Umbilical Artery

28  
29 WMO – Medical Research Involving Human Subjects Act  
30  
31  
32  
33  
34  
35  
36

## 37 **DECLARATIONS**

### 38 **Ethics and dissemination**

39  
40 This study was submitted to the Ethics Committee of the University Medical Center Utrecht  
41  
42 (METC NedMec, registration number 22/613), which confirmed that the Medical Research  
43  
44 Involving Human Subjects Act (WMO) did not apply to this study. Therefore, an official approval  
45  
46 was not required under the WMO (18). In addition, the need for informed consent was waived  
47  
48 as an exception was made in accordance with the General Data Protection Regulation (19).  
49  
50 Results of this study will be presented at conferences and published in peer-reviewed journals.  
51  
52  
53  
54  
55  
56  
57  
58

### 59 **Patient and Public Involvement**

60

1  
2  
3 Patients or the public were not involved in the design, conduct, reporting or dissemination  
4  
5 plans of this study.  
6  
7  
8  
9

### 10 **Competing interests**

11  
12 The authors declare no conflict of interest.  
13  
14  
15  
16

### 17 **Funding**

18  
19 This work was supported by Fonds Stichting Gezondheidszorg Spaarneland grant number  
20  
21 2021381 to J. Kooiman. This funding body was not involved in the development of the study  
22  
23 design and will not be involved in conducting or reporting the results of the study.  
24  
25  
26  
27  
28  
29

### 30 **Acknowledgements**

31  
32 Not applicable.  
33  
34  
35  
36

### 37 **Author's contributions**

38  
39 JK, TL, WG, SG, FG, WO, EK, ES, and MM contributed to the overall design of the study and JK  
40  
41 is the principal investigator of the study. All authors read and approved the final version for  
42  
43 submission.  
44  
45  
46  
47  
48  
49

### 50 **Open access**

51  
52 This is an open access article distributed in accordance with the Creative Commons Attribution  
53  
54 Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build  
55  
56 upon this work non-commercially, and license their derivative works on different terms,  
57  
58 provided the original work is properly cited, appropriate credit is given, any changes made  
59  
60

1  
2  
3 indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-](http://creativecommons.org/licenses/by-nc/4.0/)  
4 [nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)  
5  
6  
7  
8  
9

### 10 **Corresponding author**

11  
12  
13 Correspondence to J. Kooiman ([j.kooiman@umcutrecht.nl](mailto:j.kooiman@umcutrecht.nl)).  
14  
15  
16

### 17 **REFERENCES**

- 18  
19  
20 1. Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al. FIGO  
21 (international Federation of Gynecology and obstetrics) initiative on fetal growth: best  
22 practice advice for screening, diagnosis, and management of fetal growth restriction.  
23 Int J Gynecol Obstet. 2021;152(S1):3–57.  
24  
25 2. Pels A, Beune IM, van Wassenaer-Leemhuis AG, Limpens J, Ganzevoort W. Early-onset  
26 fetal growth restriction: A systematic review on mortality and morbidity. Acta Obstet  
27 Gynecol Scand. 2020;99(2):153–66.  
28  
29 3. Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB, et al. Perinatal morbidity  
30 and mortality in early-onset fetal growth restriction: Cohort outcomes of the trial of  
31 randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol.  
32 2013;42(4):400–8.  
33  
34 4. Lees CC, Marlow N, Van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, et al.  
35 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very  
36 preterm fetal growth restriction (TRUFFLE): A randomised trial. Lancet.  
37 2015;385(9983):2162–72. doi:10.1016/S0140-6736(14)62049-3  
38  
39 5. Crovetto F, Crispi F, Scazzocchio E, Mercade I, Meler E, Figueras F, et al. First-trimester  
40 screening for early and late small-for-gestational-age neonates using maternal serum  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 biochemistry, blood pressure and uterine artery Doppler. *Ultrasound Obstet Gynecol.*  
4  
5 2014;43(1):34–40.  
6  
7
- 8 6. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction.  
9  
10 *Am J Obstet Gynecol.* 2018;218(2):S745–61. doi:10.1016/j.ajog.2017.11.577  
11  
12
- 13 7. Zur RL, Kingdom JC, Parks WT, Hobson SR. The Placental Basis of Fetal Growth  
14  
15 Restriction. *Obstet Gynecol Clin North Am.* 2020;47(1):81–98.  
16  
17
- 18 8. Maulik D. Fetal growth restriction: the etiology. *Clin Obstet Gynecol.* 2006  
19  
20 Jun;49(2):228–35.  
21  
22
- 23 9. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating  
24  
25 fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev.*  
26  
27 2020;2021(2).  
28  
29
- 30 10. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus  
31  
32 Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal  
33  
34 Outcomes. *JAMA.* 1995 Feb;273(5):413–8.  
35  
36
- 37 11. Melamed N, Shah J, Soraisham A, Yoon EW, Lee SK, Shah PS, et al. Association between  
38  
39 antenatal corticosteroid administration-to-birth interval and outcomes of preterm  
40  
41 neonates. *Obstet Gynecol.* 2015;125(6):1377–84.  
42  
43
- 44 12. Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, et al. Long-term  
45  
46 outcomes after repeat doses of antenatal corticosteroids. *N Engl J Med.* 2007 Sep  
47  
48 20;357(12):1190–8. doi:10.1056/NEJMoa071453  
49  
50
- 51 13. Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, et al. Monitoring of  
52  
53 fetuses with intrauterine growth restriction: a longitudinal study. *Ultrasound Obstet*  
54  
55 *Gynecol.* 2001 Dec;18(6):564–70. doi:10.1046/j.0960-7692.2001.00590.x  
56  
57
- 58 14. Committee on Practice Bulletins. ACOG Practice Bulletin - Fetal Growth Restriction.  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Obstet Gynecol [online]. 2021;137(2). <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/02/fetal-growth-restriction> (accessed 11 June 2022).
15. Royal College of Obstetricians and Gynaecologists. Green-Top Guideline 31: The Investigation and Management of the Small-for-Gestational-Age Fetus. RCOG Green-top Guidel [online]. 2014;(31):1–34. [https://www.rcog.org.uk/globalassets/documents/guidelines/gtg\\_31.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdf) (accessed 11 June 2022).
16. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. *Ultrasound Obstet Gynecol*. 2020;56(2):298–312.
17. Stanislavsky A. Severe IUGR with critical dopplers [online]. [www.radiopaedia.org](http://www.radiopaedia.org) (accessed 11 Aug 2022).
18. Wet medisch-wetenschappelijk onderzoek met mensen [online]. Wettenbank Nederlandse Overheid. 2022. <https://wetten.overheid.nl/jci1.3:c:BWBR0009408&z=2022-07-01&g=2022-07-01> (accessed 9 Nov 2022).
19. General Data Protection Regulation (GDPR) [online]. 2018. <https://gdpr-info.eu/> (accessed 9 Nov 2022).
20. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound Obstet Gynecol*. 2016;48(3):333–9.
21. Castor Electronic Data Capture (EDC) [online]. <https://www.castoredc.com/electronic-data-capture-system/> (accessed 11 June 2022).

- 1  
2  
3 22. Healy P, Gordijn SJ, Ganzevoort W, Beune IM, Baschat A, Khalil A, et al. A Core  
4 Outcome Set for the prevention and treatment of fetal GROWth restriction: deVeloPing  
5 Endpoints: the COSGROVE study. *Am J Obstet Gynecol*. 2019;221(4):339.e1-339.e10.  
6  
7  
8  
9  
10 23. Jenkins DA, Sperrin M, Martin GP, Peek N. Dynamic models to predict health  
11 outcomes: current status and methodological challenges. *Diagnostic Progn Res*.  
12 2018;2(1):1–9.  
13  
14  
15 24. Fontein DBY, Klinten Grand M, Nortier JWR, Seynaeve C, Meershoek-Klein Kranenbarg  
16 E, Dirix LY, et al. Dynamic prediction in breast cancer: proving feasibility in clinical  
17 practice using the TEAM trial. *Ann Oncol Off J Eur Soc Med Oncol*. 2015  
18 Jun;26(6):1254–62.  
19  
20  
21 25. R Core Team (2021). R: A language and environment for statistical computing. [online].  
22 R Foundation for Statistical Computing, Vienna, Austria. <https://www.r-project.org/>.  
23 (accessed 9 Nov 2022).  
24  
25  
26 26. Gulliford MC, Adams G, Ukoumunne OC, Latinovic R, Chinn S, Campbell MJ. Intra-class  
27 correlation coefficient and outcome prevalence are associated in clustered binary data.  
28 *J Clin Epidemiol*. 2005;58(3):246–51.  
29  
30  
31 27. Hemming K, Girling AJ, Sitch AJ, Marsh J, Lilford RJ. Sample size calculations for cluster  
32 randomised controlled trials with a fixed number of clusters. *BMC Med Res Methodol*.  
33 2017;17(1):8.  
34  
35  
36 28. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the  
37 sample size required for developing a clinical prediction model. *BMJ*.  
38 2020;368(March):1–12. doi:10.1136/bmj.m441  
39  
40  
41 29. Norman M, Piedvache A, Børch K, Huusom LD, Bonamy AKE, Howell EA, et al.  
42 Association of short antenatal corticosteroid administration-to-birth intervals with  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 survival and morbidity among very preterm infants results from the EPICE cohort.  
4  
5 JAMA Pediatr. 2017;171(7):678–86.  
6  
7
- 8 30. Ting JY, Kingdom JC, Shah PS. Antenatal glucocorticoids, magnesium sulfate, and  
9  
10 mode of birth in preterm fetal small for gestational age. *Am J Obstet Gynecol.*  
11  
12 2018;218(2):S818–28. doi:10.1016/j.ajog.2017.12.227  
13  
14
- 15 31. Walker D-M, Marlow N, Upstone L, Gross H, Hornbuckle J, Vail A, et al. The Growth  
16  
17 Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of  
18  
19 delivery in fetal growth restriction. *Am J Obstet Gynecol.* 2011 Jan;204(1):34.e1-9.  
20  
21
- 22 32. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al.  
23  
24 Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management  
25  
26 recommendations for international practice. *Hypertension.* 2018;72(1):24–43.  
27  
28
- 29 33. Knight M. Eclampsia in the United Kingdom 2005. *BJOG An Int J Obstet Gynaecol.*  
30  
31 2007;114(9):1072–8.  
32  
33
- 34 34. Hoftiezer L, Hof MHP, Dijs-Elsinga J, Hogeveen M, Hukkelhoven CWPM, van Lingen RA.  
35  
36 From population reference to national standard: new and improved birthweight charts.  
37  
38 *Am J Obstet Gynecol.* 2019 Apr;220(4):383.e1-383.e17.  
39  
40
- 41 35. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 2001  
42  
43 Jun;163(7):1723–9. doi:10.1164/ajrccm.163.7.2011060  
44  
45
- 46 36. Neu J, Walker WA. Necrotizing enterocolitis. *N Engl J Med.* 2011 Jan 20;364(3):255–64.  
47  
48 doi:10.1056/NEJMra1005408  
49  
50
- 51 37. Pellegrin S, Munoz FM, Padula M, Heath PT, Meller L, Top K, et al. Neonatal seizures:  
52  
53 Case definition & guidelines for data collection, analysis, and presentation of  
54  
55 immunization safety data. *Vaccine.* 2019;37(52):7596–609.  
56  
57  
58 doi:10.1016/j.vaccine.2019.05.031  
59  
60



- 1  
2  
3 38. Gopagondanahalli KR, Li J, Fahey MC, Hunt RW, Jenkin G, Miller SL, et al. Preterm  
4 hypoxic-ischemic encephalopathy. *Front Pediatr.* 2016;4(OCT):1–10.  
5  
6  
7  
8 39. De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The  
9 Montreux definition of neonatal ARDS: biological and clinical background behind the  
10 description of a new entity. *Lancet Respir Med.* 2017 Aug;5(8):657–66.  
11  
12  
13  
14  
15 40. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal  
16 and intraventricular hemorrhage: a study of infants with birth weights less than 1,500  
17 gm. *J Pediatr.* 1978 Apr;92(4):529–34.  
18  
19  
20  
21  
22 41. Martinez-Biarge M, Groenendaal F, Kersbergen KJ, Benders MJNL, Foti F, van Haastert  
23 IC, et al. Neurodevelopmental Outcomes in Preterm Infants with White Matter Injury  
24 Using a New MRI Classification. *Neonatology.* 2019;116(3):227–35.  
25  
26  
27  
28  
29 42. Bayley N. The Bayley scales of infant and toddler development. San Antonio, TX:  
30 Harcourt Assessment, Inc. 2006.  
31  
32  
33  
34 43. van Baar A, Steenis L, Verhoeven M, Hessen D. Bayley-III-NL; Technische handleiding.  
35 Amsterdam, the Netherlands.: Pearson Assessment and Information B.V.; 2014.  
36  
37  
38  
39 44. Bax M, Goldstein M, Rosenbaun P, Leviton A, Paneth N, Dan B, et al. Proposed  
40 definition and classification of cerebral palsy, April 2005. *Dev Med Child Neurol.*  
41 2005;47(8):571.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TITLES AND LEGENDS FIGURES

**Figure 1.** Timing strategies regarding antenatal CCS administration in early-onset FGR in the Netherlands


Abbreviations: CCS, corticosteroids; PI, pulsatility index; UA, umbilical artery. Reference image strategy "B": (17)

**Figure 2.** Study design and duration of follow-up

Abbreviations: FGR, fetal growth restriction; CCS, corticosteroids; PI, pulsatility index; UA, umbilical artery; AEDV, absent end-diastolic velocity; REDV, reversed end-diastolic velocity; FU, follow-up; CA, corrected age. Reference image strategy "B": (17)

For peer review only





**Supplementary file 1****COSGROVE: Core Outcome Set for FGR supplemented with other relevant endpoi**

Domain	Outcome
<b>Maternal</b>	Pre-eclampsia
	Eclampsia
	Maternal death
	Mode of birth
<b>Fetal</b>	Stillbirth/livebirth
<b>Neonatal</b>	Gestational age at birth
	Preterm birth
	Extremely preterm birth
	Birthweight
	Birthweight <10 <sup>th</sup> percentile
	Birthweight <3 <sup>rd</sup> percentile
	Need for mechanical ventilation
	Bronchopulmonary dysplasia, moderate and severe

1	
2	
3	
4	
5	
6	
7	
8	
9	Necrotizing enterocolitis $\geq 2$ according to
10	the Bell's stages
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	Neonatal seizures
28	
29	
30	
31	
32	
33	
34	
35	Hypoxic-ischemic encephalopathy
36	
37	
38	
39	Neonatal death
40	
41	In-hospital death
42	
43	Respiratory distress syndrome
44	
45	
46	
47	
48	
49	Intraventricular hemorrhage
50	
51	
52	
53	
54	Cystic periventricular leukomalacia
55	
56	
57	
58	Retinopathy of prematurity
59	
60	

1 2 3 4 5 6 7 8	Neonatal sepsis
9 10 11 12 13 14	Persistent pulmonary hypertension of the newborn
15 16	Duration of supplemental oxygen therapy during admission
17 18 19	Need for mechanical ventilation < 72 hours post-partum
20 21 22 23 24 25 26 27 28 29 30 31 32	<b>Childhood (Long-term follow-up)</b> Cognitive impairment (available for children born before 30 weeks gestational age, for children born after a longer pregnancy duration follow-up management varies between clinics)
33 34 35 36 37 38 39 40 41 42 43	Motor impairment (available for children born before 30 weeks gestational age, for children born after a longer pregnancy duration follow-up management varies between clinics)
44 45 46 47 48 49	Cerebral palsy
50 51	Hearing impairment
52 53 54 55 56 57 58 59 60	Visual impairment

**Terms with definitions (20)****Definition**

Gestational hypertension accompanied by one or more of the following new-onset conditions at or after 20 weeks' gestation:

1. Proteinuria;
2. Other maternal organ dysfunction, including: Acute kidney injury (creatinine  $\geq 90 \mu\text{mol/L}$ ;  $1 \text{ mg/dL}$ ); liver involvement (elevated transaminases e.g. ALT or AST  $> 40 \text{ IU/L}$ ) with or without right upper quadrant or epigastric abdominal pain); neurological complications (examples include eclampsia, altered mental status, blindness, stroke, clonus, severe headaches, persistent visual scotomata); haematological complications (thrombocytopenia – platelet count below  $150,000/\mu\text{L}$ , diffuse intravascular coagulation, hemolysis);
3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery Doppler wave form analysis, or stillbirth) (30)

Eclampsia refers to the occurrence of new-onset, generalized, tonic-clonic seizures or coma in a woman with preeclampsia (31)

Death of mother during pregnancy or the first six weeks after delivery (postpartum).

Defined as either vaginal or caesarean section.

Stillbirth: death of fetus ante- or intrapartum (20)

Livebirth: birth of a living neonate

Time in weeks and days

Delivery at  $< 37.0$  weeks gestation

Delivery at  $< 28.0$  weeks gestation

Weight at time of birth in grams (g)

Presence of birthweight below the 10<sup>th</sup> percentile according to Hoftiezer *et al.* (32)

Presence of birthweight below the 3<sup>rd</sup> percentile according to Hoftiezer *et al.* (32)

Need for intubation and mechanical ventilation to support gas exchange

Bronchopulmonary dysplasia is diagnosed if gestational age  $< 32$  weeks: at a postmenstrual age of 36 weeks,  $> 21\%$  oxygen has been administered cumulatively for 28 or more days (33)



- 1  
2 ○ Moderate: Need for <30% oxygen at 36  
3 weeks postmenstrual age  
4 ○ Severe: Need for ≥30% oxygen and/or  
5 positive pressure (positive pressure ventilation  
6 or continuous positive airway pressure) at 36  
7 weeks postmenstrual age

8  
9 Definitive medical necrotising enterocolitis:

- 10 • Abdominal distention with pneumatosis  
11 intestinalis, portal venous gas, or both.  
12 • Other radiographic signs such as fixed,  
13 dilated loops of intestine and ileus patterns are  
14 not pathognomonic but should be treated as  
15 such.

16  
17 Surgical necrotising enterocolitis:

- 18 • Free intraperitoneal air on abdominal  
19 radiograph after initial medical signs and  
20 symptoms.  
21 • Persistent ileus pattern, abdominal distension,  
22 and radiographs that show an absence of  
23 bowel gas, coupled with deteriorating clinical  
24 and laboratory values. (34)

25  
26  
27 Transient electrographic change in the brain  
28 due to an abnormal, excessive or synchronous  
29 neuronal activity either with the occurrence of  
30 clinical signs (electro-clinical) or without them  
31 (electrographic only) in preterm infants up to  
32 44 weeks of post menstrual age (35)

33  
34  
35 Clinical syndrome that results from a severe or  
36 prolonged hypoxic-ischemic episode before or  
37 during birth (36)

38  
39 Death of the neonate within 28 days after birth

40  
41 Death of the neonate until hospital-discharge

42  
43 Neonatal respiratory distress syndrome,  
44 characterized by extensive lung inflammation  
45 and surfactant catabolism leading to lung  
46 dysfunction, with need for surfactant (37)

47  
48  
49 Intraventricular hemorrhage grade 3 according  
50 to Papile *et al.*, venous infarction,  
51 posthemorrhagic ventricular dilatation needing  
52 treatment (38)

53  
54 Cystic periventricular leukomalacia  
55 characterized by diffuse injury of the white  
56 matter, which possibly leads to cerebral palsy  
57 (39)

58  
59 Retinopathy of prematurity with plus disease  
60 for which treatment is needed

- Early-onset: neonatal sepsis in the first 72 hours of age
- Late-onset: neonatal sepsis after the first 72 hours of age
- Clinical: based on clinical condition
- Culture-proven

Persistent pulmonary hypertension of the newborn occurs in case of persistent abnormally, elevated pulmonary vascular resistance after birth, leading to severe hypoxemia

Duration of supplemental oxygen therapy during admission (in days)

Need for intubation and mechanical strategies to support gas exchange within 72 hours after birth

A decreased ability of cognitive function using the Dutch Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III-NL) at a corrected age of 24 months. Severe disability will be defined as a Bayley Mental Development Index score more than 2SD below the mean score (i.e.  $\leq 70$ ). Moderate disability will be defined as a Bayley Mental Development Index score 1 to 2 SD below the mean score (i.e. 71-85) (40,41)

A decreased ability of fine and gross motor function using part of the Dutch Bayley Scales and Infant and Toddler Development, Third Edition (BSID-III-NL) at corrected age of 24 months. Severe disability will be defined as a score of more than 2 SD below the mean score (i.e.  $\leq 70$ ). Moderate disability will be defined as a score 1 to 2SD below the mean score (i.e. 71-85) (40,41)

A group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain (42)

A decreased ability of the auditory system requiring hearing aids or deafness

A decreased ability of the visual system requiring aids or blindness

# BMJ Open

## OPTimal TIMing of antenatal CORTicosteroid administration in pregnancies complicated by early-onset fetal growth REstriction (OPTICORE): study protocol of a multicentre, retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070729.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Feb-2023
Complete List of Authors:	<p>van de Meent, Mette; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Kleuskens, D.; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Ganzevoort, Wessel; Amsterdam University Medical Centres, Department of Obstetrics and Gynaecology          Gordijn, Sanne; University Medical Centre Groningen, Department of Obstetrics and Gynaecology          Kooi, E.; University Medical Centre Groningen, Department of Neonatology          Onland, Wes; Amsterdam University Medical Centres, Department of Paediatrics          van Rijn, Bas; Erasmus MC, Department of Obstetrics and Gynaecology          Duvekot, J.J.; Erasmus MC, Department of Obstetrics and Gynaecology          Kornelisse, René; Erasmus MC Sophia, Department of Paediatrics          Al-Nasiry, Salwan; Maastricht UMC+, Department of Obstetrics and Gynaecology          Jellema, R.; Maastricht UMC+, Department of Neonatology          Knol, H. ; Isala Zwolle, Department of Obstetrics and Gynaecology          Manten, G.; Isala Zwolle, Department of Obstetrics and Gynaecology          Mulder-deTollenaere, S. ; Isala Zwolle, Department of Neonatology          Derks, J. ; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Groenendaal , Floris ; University Medical Centre Utrecht, Department of Neonatology          Bekker, Mireille; UMC Utrecht, Department of Obstetrics and Gynaecology          Schuit, Ewoud; Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht          Lely, Titia; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology          Kooiman, J.; University Medical Centre Utrecht, Department of Obstetrics and Gynaecology</p>
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Epidemiology, Paediatrics

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Keywords:	NEONATOLOGY, EPIDEMIOLOGY, OBSTETRICS

SCHOLARONE™  
Manuscripts

# OPTimal Timing of antenatal COrticosteroid administration in pregnancies complicated by early-onset fetal growth REstriction (OPTICORE): study protocol of a multicentre, retrospective cohort study

M. van de Meent, MD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, the Netherlands

D. G. Kleuskens, BSc, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

W. Ganzevoort, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands

S. J. Gordijn, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, University Medical Center Groningen, the Netherlands

E. M. W. Kooi, MD, PhD, Associate Professor, department of Neonatology, University Medical Center Groningen, the Netherlands

W. Onland, MD, PhD, department of Neonatology, Amsterdam University Medical Center, location AMC, Amsterdam and Amsterdam Reproduction & Development, Amsterdam, the Netherlands

B. B. van Rijn, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, the Netherlands

J. J. Duvekot, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, the Netherlands

R. F. Kornelisse, MD, PhD, department of Neonatology, Erasmus Medical Center, Rotterdam, the Netherlands

S. Al-Nasiry, MD, PhD, department of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, the Netherlands

R. Jellema, MD, PhD, department of Neonatology, Maastricht University Medical Center, Maastricht, the Netherlands

H. M. Knol, MD, PhD, department of Obstetrics and Gynaecology, Isala Zwolle, the Netherlands

G. T. R. Manten, MD, PhD, department of Obstetrics and Gynaecology, Isala Zwolle, the Netherlands

S. M. Mulder-de Tollenaer, MD, PhD, department of Neonatology, Isala Zwolle, the Netherlands

J. B. Derks, MD, PhD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

F. Groenendaal, MD, PhD, Associate Professor, department of Neonatology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

M. N. Bekker, MD, PhD, Full Professor, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

E. Schuit, PhD, Assistant Professor, University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands

A. T. Lely, MD, PhD, Associate Professor, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands

J. Kooiman, MD, PhD, department of Obstetrics and Gynaecology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Lundlaan 6, 3584 EA, Utrecht, [j.kooiman@umctrecht.nl](mailto:j.kooiman@umctrecht.nl)\*

\*Corresponding author

Word count: 3202

## ABSTRACT

### Introduction

Early-onset fetal growth restriction (FGR) requires timely, often preterm, delivery to prevent fetal hypoxia causing stillbirth or neurologic impairment. Antenatal corticosteroids (CCS) administration reduces neonatal morbidity and mortality following preterm birth, most effectively when administered within one week preceding delivery. Optimal timing of CCS administration is challenging in early-onset FGR, as the exact onset and course of fetal hypoxia is unpredictable. International guidelines do not provide a directive on this topic. In the Netherlands two timing strategies are commonly practiced: administration of CCS when the umbilical artery shows A) a pulsatility index above the 95<sup>th</sup> centile; B) absent or reversed end-diastolic velocity (a more progressed disease state). This study aims to 1) use practice variation to compare CCS timing strategies in early-onset FGR on fetal and neonatal outcomes; 2) develop a dynamic tool to predict the time interval in days until delivery, as a novel timing strategy for antenatal CCS in early-onset FGR.

### Methods and analysis

A multicentre, retrospective cohort study will be performed including pregnancies complicated by early-onset FGR in six tertiary hospitals in the Netherlands in the period between 2012-2021 (estimated sample size n=1800). Main exclusion criteria are multiple pregnancies and fetal congenital or genetic abnormalities. Routinely collected data will be extracted from medical charts. Primary outcome for the comparison of the two CCS timing strategies is a composite of perinatal, neonatal and in-hospital mortality. Secondary outcomes include the COSGROVE core outcomes set for FGR. A multivariable, mixed-effects model will be used to compare timing

1  
2  
3 strategies on study outcomes. Primary outcome for the dynamic prediction tool is 'days until  
4  
5 birth'.  
6  
7  
8  
9

### 10 **Ethics and dissemination**

11  
12 The need for ethical approval was waived by the Ethics Committee (University Medical Center  
13  
14 Utrecht). Results will be published in open-access, peer-reviewed journals and disseminated by  
15  
16 presentations at scientific conferences.  
17  
18  
19  
20  
21

### 22 **Trial registration**

23  
24  
25 ClinicalTrials.gov: NCT05606497.  
26  
27  
28  
29

### 30 **Strengths and limitations of this study**

- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- This study includes a large sample of early-onset FGR patients using a consensus-based and internationally accepted FGR definition.
  - This study uses novel techniques in prediction research to develop a dynamic prediction tool to forecast the time interval in days until birth.
  - The outcomes of our study are in line with landmark trials in FGR and a core outcomes set for this specific patients population (COSGROVE).
  - Residual confounding could be a possible limitation of our observational study, caused by other (unaccounted) differences in obstetric and neonatal routine care (other than antenatal CCS timing strategies) between participating hospitals that might influence study outcome measures.
  - Follow-up on secondary outcomes of the offspring, including long-term follow-up, might not be complete in all patients.

## BACKGROUND

Early-onset fetal growth restriction (FGR) is defined as failure of a fetus to meet its growth potential, with its detection before 32 weeks of pregnancy. Early-onset FGR occurs in approximately 0.5-1% of all pregnancies and is a notable cause of stillbirth (2%), neonatal morbidity (24%) and mortality (8-19%) (1-5). In developed countries, early-onset FGR is most commonly caused by placental dysfunction leading to unmet fetal metabolic and gaseous demands (6,7). In a prolonged and increasing hypoxic state, the anticipated risks of stillbirth rise. Active fetal surveillance of early-onset FGR pregnancies is therefore warranted and consists of ultrasound (fetal Doppler sonography) and analysis of the fetal heart rate pattern (cardiotocography) to detect critical fetal hypoxia and instigate timely, often preterm, delivery. Alternatively, maternal health issues can necessitate pre-term delivery as early-onset FGR frequently coincides with (pre-)eclampsia (8).

Antenatal corticosteroids (CCS) lower the risks of neonatal morbidity and mortality following spontaneous preterm birth (9,10). Literature suggests that antenatal CCS treatment may be most beneficial in reducing adverse neonatal outcome when a completed course of CCS (i.e. two doses of betamethasone or dexamethasone at an 24 hours interval) is administered one to seven days prior to birth (adjusted odds ratio 1.46, 95% confidence interval (CI) 1.20-1.77 in comparison to a time span longer than 7 days prior to birth) (11). Although the clinical benefit and possible harms of antenatal CCS therapy are subject of debate in early-onset FGR, it is one of the very few antenatal treatments that can possibly improve neonatal health. Repeated courses of CCS should be avoided, as they have been associated with decreased birthweight, length, head circumference and higher rates of cerebral palsy (12,13). Therefore, adequate timing of CCS administration is likely to be important, also in the setting of early-onset FGR pregnancies when preterm birth is anticipated.



1  
2  
3 There is consensus that repetitive decelerations on the cardiotocography registration  
4 reflect fetal distress and an increased risk of fetal death (13). They are thus an important trigger  
5 to initiate birth. Unfortunately, it is difficult to predict when these repetitive decelerations will  
6 occur during the period of active fetal surveillance, which makes it challenging to administer  
7 CCS within the ideal timeframe of 7 days prior to birth. International guidelines do not provide  
8 a clear directive regarding the timing of CCS treatment in early-onset FGR (1,14–16). In the  
9 Netherlands, two timing strategies regarding antenatal CCS administration in early-onset FGR  
10 are currently being practiced (Figure 1 (17)):

- 23 - Strategy "A": administration of CCS when the pulsatility index (PI) of the umbilical artery  
24 (UA) becomes abnormal (i.e. > 95th percentile), irrespective of its end-diastolic  
25 waveform.  
26  
27
- 28 - Strategy "B": administration of CCS when absent or reversed end-diastolic velocity of  
29 the UA is detected, thus in a more progressed disease state as compared to strategy A.  
30  
31  
32  
33

34 This study aims to compare these two timing strategies of antenatal CCS administration in  
35 early-onset FGR on a composite outcome of perinatal, neonatal and in-hospital mortality  
36 (definitions listed in 'methods' section below). With that, we aim to inform clinicians about the  
37 optimal timing management of antenatal CCS administration to improve outcomes of  
38 pregnancies complicated by early-onset FGR. In addition, we aim to develop a dynamic,  
39 prediction tool to regularly determine the time interval until birth in days during the period of  
40 active fetal surveillance. Ultimately, the use of such a dynamic risk tool could be used as an  
41 additional timing strategy for CCS treatment in early-onset FGR with the aim to improve  
42 neonatal outcome.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Study design and setting

This multicentre, retrospective cohort study is designed to mimic a cluster randomized controlled trial (RCT). The study will be performed in six tertiary teaching hospitals in the Netherlands, all equipped with a level III neonatal intensive care unit. These hospitals were selected based on their local guidelines for FGR management (i.e. CCS timing strategy in early-onset FGR). The selection of these six hospitals resulted in an even distribution of the hospitals over the two CCS timing strategies (as is custom in a cluster-RCT) and a sufficient sample size of our study (see power calculation). To add, hospitals have a high adherence rate regarding the guidelines for the management of FGR pregnancies and, therefore, there is no within-hospital variation between physicians on this matter.

Patients will be included when diagnosed with early-onset FGR between 2012 and 2021. Neonates were actively managed at 24 weeks of gestational age since 2010 in the Netherlands. Therefore, and considering the learning curve neonatologists experienced in the first two years of this new policy, patients will be included from 2012 onwards. This study protocol was assessed by the Ethics Committee of the University Medical Center Utrecht (METC NedMec, registration number 22/613), which confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (18). In addition, the need for informed consent was waived as an exception was made in accordance with the General Data Protection Regulation as A) processing the data is necessary with a view to scientific research; B) the research is of public interest; C) requesting consent requires disproportionate effort (i.e. the number of patients is too high); D) the research embodies such assurances that the privacy of the data subject will not be disproportionately harmed (19). A Data Management Plan has been drawn up and participating centers had to be rewarded with a ISO27001/NEN7510 certificate

1  
2  
3 to meet the General Data Protection Regulation requirements (19). Patients or the public were  
4  
5 not involved in the design, or conduct, or reporting, or dissemination plans of our research.  
6  
7  
8  
9

### 10 **Study population**

11  
12 To be eligible for inclusion, a patient must meet all of the following criteria: 1) Early-onset FGR  
13  
14 in accordance with the consensus-based definition of Gordijn *et al.* (20); 2) Singleton  
15  
16 pregnancy; 3) Age  $\geq$  18 years; 4) Consented active, neonatal management after counselling  
17  
18 (thus having an indication for CCS administration in case of birth < 34 weeks of gestational  
19  
20 age). Exclusion criteria are 1) Multiple pregnancies; 2) Fetal congenital abnormalities or  
21  
22 antenatal diagnosed genetic disorders; 3) Patients who stated that their patient or offspring  
23  
24 data may not be used for scientific research.  
25  
26  
27  
28  
29  
30  
31

### 32 **Data collection**

33  
34 Patients will be identified using parturition records. Data will be captured in a CASTOR  
35  
36 electronic case report form, a Good Clinical Practice compliant Electronic Data Capture system  
37  
38 (21).  
39  
40

41  
42 Medical records will be scrutinized to extract the patient characteristics of mothers as well as  
43  
44 the offspring. The offspring is often transferred to a level II neonatology unit after being treated  
45  
46 in the level III neonatal intensive care unit of the participating hospitals. To complete  
47  
48 information on neonatal study outcomes, admission and discharge letters of these patient  
49  
50 transfers will be used to ensure complete follow-up assessment. In addition, data collection  
51  
52 regarding the primary outcome is safeguarded by a national registration on pregnancy  
53  
54 outcomes (PERIDOS). Information on neurodevelopment will be obtained from follow-up  
55  
56  
57  
58  
59  
60

assessments in the participating perinatal centers or from letters of the local paediatricians. All variables and outcomes that will be collected are summarized in Table 1.

**Table 1.** Patient characteristics of the mother and the offspring

Maternal characteristics	Pregnancy characteristics	Characteristics of the offspring
Age	Gestational age at time of diagnosis	Sex
Ethnic background	Gravidity	Gestational age at birth
Smoking status	Parity	Birth weight
Drug use	Time between corticosteroid administration and birth (days)	Birth weight centile (Hoftiezer)
Body Mass Index	Mode of delivery (caesarean or vaginal)	Apgar scores at 5 minutes
Transfer to other perinatal centers before delivery	<u>Obstetric history</u> Previous pregnancy affected by fetal growth restriction, pre-eclampsia, (iatrogenic) preterm birth or diabetes gravidarum.	Arterial and venous pH with base excess
<u>Pre-existent disorders</u> Chronic kidney disease; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Antiphospholipid Syndrome; Diabetes; Chronic Hypertension; Other medical disease affecting maternal or neonatal outcome	<u>Hypertensive disorders of pregnancy</u> Pregnancy-Induced Hypertension; Pre-eclampsia	<u>Mechanical ventilation</u> Need for mechanical ventilation during admission, whether this was <72 hours after birth and the duration (days).
	<u>Other pregnancy-related disorders</u> Pregnancy cholestasis; Gestational diabetes	Perinatal, neonatal and in-hospital mortality
	<u>Ultrasound-based markers (of each performed ultrasound examination)</u> Pulsatility index of umbilical artery; End-diastolic velocity waveform umbilical artery; Estimated fetal weight; Pulsatility index of middle cerebral artery; Cerebroplacental Ratio; Pulsatility index of veins ductus venosus; Atrial systolic velocity of ductus venosus; Presence of echodense fetal bowel	<u>Adverse outcome measures</u> Respiratory Distress Syndrome; Necrotizing Enterocolitis $\geq 2$ according to the Bell's stages; Bronchopulmonary Dysplasia, moderate and severe; Intraventricular Hemorrhage grade 3, venous infarction, posthemorrhagic ventricular dilatation; Cystic Periventricular Leukomalacia; Retinopathy of prematurity with plus disease to which treatment is needed ; Early and delayed neonatal sepsis, culture-proven or clinically suspected; Persistent pulmonary hypertension of the newborn
	<u>Cardiotocography registration</u> Short-term variation (if available); Presence of repetitive decelerations	Duration supplemental oxygen during admission
	Fetal death	Long-term follow-up

## Outcomes

### *Objective 1) Comparison of two main timing strategies of CCS in early-onset FGR*

The primary outcome is defined as a composite of perinatal, neonatal and in-hospital mortality.

Follow-up for this endpoint is defined as time between diagnosis of early-onset FGR and

1  
2  
3 perinatal, neonatal and in-hospital mortality, or to discharge to home. Perinatal mortality will  
4  
5 be defined as death from 22 completed weeks of gestation up to seven days following birth,  
6  
7 neonatal mortality as death within 28 days following birth and in-hospital mortality as death  
8  
9 from birth up to hospital discharge of the infant (22). Secondary outcomes for this study  
10  
11 objective are defined in accordance with the Core Outcomes Set for FGR (COSGROVE)-study  
12  
13 supplemented with other relevant maternal outcomes (23), see Supplementary file 1 (24-36).  
14  
15 Follow-up on secondary maternal outcomes ends after six weeks post-partum. Follow-up on  
16  
17 offspring outcomes is extended until two-years of corrected age (Figure 2 (17)). Data regarding  
18  
19 the long-term follow up will be collected if available (i.e. at least for children born before 30  
20  
21 weeks of gestational age or with a birth weight <1000 grams). Follow-up management for  
22  
23 children born after a longer pregnancy duration varies between hospitals.  
24  
25  
26  
27  
28  
29  
30  
31

32 *Objective 2) Development of a dynamic prediction tool of days until birth*

33  
34 We will develop a dynamic prediction model to regularly determine the time interval until birth  
35  
36 during the period of active fetal surveillance. Such a dynamic prediction model could alert  
37  
38 physicians about the upcoming pre-term delivery and can therefore serve as a trigger for CCS  
39  
40 administration. Traditionally, prediction models are based on 'static' information, not  
41  
42 considering the vast amount of new information that becomes available on a daily basis. To  
43  
44 better align with clinical care, dynamic prediction could be used, a novel technique in the risk  
45  
46 assessment research field (37). Daily updates can be generated on the outcome of "days until  
47  
48 birth" by adding new information about maternal or fetal health, e.g. retrieved by  
49  
50 ultrasonography and CTG-registration routinely used in FGR pregnancies, to the dynamic  
51  
52 model. This provides the physician with an up-to-date time interval assessment.  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analyses

### *Objective 1) Comparison of two main timing strategies of CCS in early-onset FGR*

As our study design mimics a cluster-RCT, we will align our statistical analysis with the methods adopted by such trials. Intra-cluster correlation should thus be considered. Primary and secondary outcomes will be compared between the two timing strategies by use of the practice variation between the participating centers using a multivariable, mixed-effects model, taking hierarchy of the data into account. Important differences in routine care between the participating centers, other than the timing strategy, and between participants across the timing strategies are considered to be important confounding variables, and will be adjusted for in the analyses. These differences in routine care will be identified by studying local, management protocols and by scheduling research meetings to discuss routine care in the participating centers. Adjusted odds ratios with 95% confidence intervals will be calculated for dichotomous outcome measures and mean with standard deviations will be calculated for continuous outcome measures (and median with interquartile range for continuous non-parametric outcomes). Timing strategy "A" will be held as reference group. For secondary outcome measures similar analyses will be performed. Exploratory subgroup analyses will be performed based on gestational age at birth (below versus above 34 weeks). The decision for this subgroup analysis was due to the fact that antenatal CCS are administered up to 34 weeks of gestation in the Netherlands. Heterogeneous treatment effects will be assessed by introducing an interaction term between the subgroup variable and the CCS treatment timing strategy to the mixed-effects model for the primary outcome. A formal test of interaction will be performed. Afterwards, the primary analysis will be repeated within each stratum of the subgroup.

## Objective 2) Development of a dynamic prediction tool of days until birth

To allow for dynamic prediction, information known at baseline as well as subsequent clinical and ultrasonographic information that becomes available will be used in a proportional baselines landmark supermodel, with days until birth as the outcome (38). Candidate predictors

**Table 2.** Candidate predictors dynamic, prediction tool

Fetal	Maternal
Estimated fetal weight	Presence of hypertensive disorders of pregnancy
Gestational age	Use of anti-hypertensive drugs
Pulsatility index umbilical artery	Use of intravenous anti-hypertensive medication
Pulsatility index cerebral middle artery	Use of magnesium sulphate
Cerebroplacental ratio	Number of hypertensive crises
Pulsatility index of veins ductus venosus	Presence of lung edema
Absence of interval growth	Progression of organ dysfunction
Repetitive decelerations on CTG	
Short-term variability	
Subjective fetal movements	

were selected based on literature and clinical practice, summarized in Table 2. For these candidate predictors, repeated measures will be gathered on the day of every follow-up ultrasonography (i.e. once or twice a week). Missing data regarding possible

predictors will be imputed by multiple imputation. The final set of predictors will be selected using backward stepwise elimination based on the Akaike Information Criterion. Internal validation using bootstrapping and subsequent shrinkage will be performed to account for potential overfitting. Model performance will be reported by assessing discrimination based on the c-statistic, and the calibration both visually using calibration plots and quantitatively using the calibration-in-the-large and calibration slope. The c-statistic, calibration-in-the-large, and calibration slope will be determined at each time point, and will be reported in a graph as a series. Statistical analyses will be conducted using the latest version of R at the time of analysis (current version 4.0.3.1.32) (39).

## Sample size calculation

*Objective 1) Comparison of two main timing strategies of CCS in early-onset FGR*

1  
2  
3 We performed a power calculation based on the fact that our study design mimics a cluster-  
4  
5 RCT. In a cluster-RCT, the statistical power of a study is determined by amongst others the  
6  
7 amount of clusters (i.e. hospitals) to be included (not patients), the intra-cluster correlation of  
8  
9 study outcomes and expected incidence of the primary outcome. We performed a power  
10  
11 calculation using three clusters (i.e. hospitals) per CCS timing strategy, an expected incidence  
12  
13 of 6.8% on our primary outcome (based on the TRUFFLE trial) and an intra-cluster correlation  
14  
15 coefficient varying between 0.001-0.0091 (3,40). Including patient data from six participating  
16  
17 hospitals (three per timing strategy) will allow us to detect a range in minimal difference on  
18  
19 the primary outcome of 1.7-4.6% with an alpha ( $\alpha$ ) of 5% and a power ( $1-\beta$ ) of 80% (3,41). We  
20  
21 expect that inclusion in six hospitals over a ten year time period will result in a total sample of  
22  
23 approximately 1800 patients, based on the production levels of the hospitals.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Objective 2) Development of a dynamic prediction tool of days until birth*

33  
34 Currently, no formal sample size calculation requirements are available for dynamic prediction  
35  
36 model development. We will use the same sample size as for objective 1. The number of  
37  
38 candidate predictors will be based on Riley *et al.*, using a margin of error of 5%, expected  
39  
40 shrinkage factor of 0.9, and Cox-Snell R squared statistic of 0.099 (42).  
41  
42  
43  
44  
45

## 46 **DISCUSSION**

47  
48 The OPTimal Timing of antenatal COrticosteroids in early-onset fetal growth REstriction  
49  
50 (OPTICORE)-study will provide a large cohort of early-onset FGR pregnancies, including patient  
51  
52 data of six participating, tertiary hospitals in the Netherlands. The results derived from this  
53  
54 study will likely provide the clinician with guidance on the optimal time frame for antenatal  
55  
56  
57  
58  
59  
60



1  
2  
3 CCS administration in this patient population. With that, we aim to improve the neonatal and  
4  
5 overall outcome for future early-onset FGR pregnancies.  
6  
7

8         There is an abundance of literature about the efficacy of antenatal CCS administration  
9  
10 in women undergoing spontaneous preterm labor. Optimal timing of antenatal CCS  
11  
12 administration – with a completed course between one and seven days before delivery – shows  
13  
14 the largest risk reduction for infant mortality compared to no administration of antenatal CCS  
15  
16 (adjusted risk ratio 0.5, 95%CI 0.4-0.6) versus a time interval of more than seven days till birth  
17  
18 (adjusted risk ratio 0.7, 95%CI 0.6-0.9) (43). Similar results were found for the outcome of severe  
19  
20 neonatal brain injury and a composite outcome measure of mortality and/or severe neonatal  
21  
22 morbidity (43). In addition, in a meta-analysis of sixteen observational studies including mainly  
23  
24 small-for-gestational age infants (i.e. birthweight <10<sup>th</sup> centile), a significant lower neonatal  
25  
26 mortality rate was found for infants exposed to antenatal CCS versus unexposed infants  
27  
28 (pooled odds ratio 0.63, 95%CI 0.46-0.86) (44). However, strong evidence for the efficacy (or  
29  
30 the absence of it) of antenatal CCS treatment in the setting of early-onset FGR is lacking, as no  
31  
32 subgroup analysis has been performed on this specific population in previously performed  
33  
34 RCTs, which would provide more robust information (9). The relative hypoxic and starved intra-  
35  
36 uterine environment in early-onset FGR likely results in higher levels of fetal endogenous  
37  
38 steroids. It remains uncertain whether antenatal CCS administration on top of this increased  
39  
40 fetal endogenous corticosteroid release is still of benefit (45). Nevertheless, international  
41  
42 guidelines on FGR advise to administer antenatal CCS in pregnancies at risk for preterm birth.  
43  
44  
45  
46  
47  
48  
49  
50  
51

52         Adequate timing of CCS treatment is challenging as the time interval until delivery in  
53  
54 early-onset FGR pregnancies is difficult to predict. Risks of stillbirth or neurological impairment  
55  
56 due to acute, on top of chronic, hypoxia have to be balanced against the risks of neonatal  
57  
58 morbidity and mortality due to prematurity. The landmark TRUFFLE and GRIT trials, that  
59  
60

1  
2  
3 assessed CTG and ultrasound parameters as triggers for timely delivery in FGR pregnancies,  
4  
5 have not resulted in clear uniform recommendations on how to time delivery (3,46). In an  
6  
7 observational study, Hecher *et al.* described the time sequence pattern in the development of  
8  
9 abnormalities in fetal Doppler patterns and CTG-registration (13). They included 110 cases of  
10  
11 FGR in a prospective, longitudinal study. However, not all pregnancies complicated by early-  
12  
13 onset FGR follow this pattern in daily practice and notably, the time line of changes in Doppler  
14  
15 patterns until delivery especially varies between patients. Additionally, maternal factors (such  
16  
17 as concomitant (pre-)eclampsia warranting birth) were ignored in the time sequence  
18  
19 monitoring-management summary. Consequently, due to the heterogeneity in time sequence  
20  
21 patterns and the continuous trade-off between fetal, neonatal, and maternal health, the  
22  
23 optimal timing of delivery remains a major clinical challenge in early-onset FGR.  
24  
25  
26  
27  
28  
29

30 The ideal design to compare the two strategies for CCS administration would be a RCT.  
31  
32 However, gathering a large enough sample for such a trial would be challenging given the low  
33  
34 incidence of both early onset-FGR and our primary outcome. We thus chose to perform a  
35  
36 retrospective cohort study over a timespan of a decade, using practice variation as an  
37  
38 instrument to mimic a cluster-RCT. Follow-up on our primary outcome is safeguarded by a  
39  
40 national registration on pregnancy outcomes (PERIDOS). However, achieving complete follow-  
41  
42 up on the various other neonatal outcomes can be challenging, especially for the secondary  
43  
44 outcome of bronchopulmonary dysplasia, as infants will be transferred from a level III neonatal  
45  
46 intensive care unit to a level II neonatology unit when they are well enough to be discharged  
47  
48 from the neonatal intensive care unit. To overcome this limitation, we will use discharge letters  
49  
50 from the level II referral hospitals to complete follow-up information. Another challenge will  
51  
52 be the patient transfers between tertiary care centers for delivery (e.g. because of unavailability  
53  
54 of capacity on the neonatal intensive care unit), as patients in our study are allocated to the  
55  
56  
57  
58  
59  
60

1  
2  
3 center where they give birth while their CCS were administered elsewhere. This results in cross-  
4  
5 over between the treatment strategies in our intention-to-treat analysis. Other differences in  
6  
7 obstetric and neonatal routine care (other than antenatal CCS timing strategies) might  
8  
9 influence the primary and secondary outcome measures namely perinatal and neonatal  
10  
11 mortality and morbidity. Analyses will be corrected for confounding factors, yet residual  
12  
13 confounding could remain an issue of our study design.  
14  
15

16  
17  
18 Strengths of this study comprise the large sample size that will be included in the study,  
19  
20 the use of a consensus-based definition of early-onset FGR and the collection of outcome  
21  
22 measures according to the COSGROVE-study with core outcomes for FGR (23). Also, we will  
23  
24 use a novel and promising technique in prediction research, namely dynamic prediction (37,38).  
25  
26 A multivariable and dynamic tool for initiation of CCS therapy might very well be superior to  
27  
28 the use of a single-variable trigger (as used by strategies A and B) in terms of predicting the  
29  
30 interval until birth. We will use this technique to develop an additional strategy to define the  
31  
32 optimal time window for antenatal CCS therapy.  
33  
34  
35

36  
37 In summary, this large cohort of early-onset FGR pregnancies will provide important  
38  
39 insights into the timing of antenatal CCS in pregnancies complicated by early-onset FGR. With  
40  
41 that, we aim to reduce perinatal, neonatal and in-hospital mortality.  
42  
43  
44  
45

#### 46 47 **LIST OF ABBREVIATIONS**

48  
49 CCS – Corticosteroids

50  
51 CI – Confidence Interval

52  
53 COSGROVE - Core Outcome Set for Fetal Growth Restriction

54  
55 FGR – Fetal Growth Restriction

56  
57 PI – Pulsatility Index  
58  
59  
60

1  
2  
3 RCT – Randomized Controlled Trial  
4

5 UA – Umbilical Artery  
6

7  
8 WMO – Medical Research Involving Human Subjects Act  
9

## 10 11 12 13 **DECLARATIONS**

### 14 15 **Ethics and dissemination**

16  
17  
18 This study was submitted to the Ethics Committee of the University Medical Center Utrecht  
19  
20 (METC NedMec, registration number 22/613), which confirmed that the Medical Research  
21  
22 Involving Human Subjects Act (WMO) did not apply to this study. Therefore, an official approval  
23  
24 was not required under the WMO (18). In addition, the need for informed consent was waived  
25  
26 as an exception was made in accordance with the General Data Protection Regulation (19). A  
27  
28 Data Management Plan has been drawn up and participating centers had to be rewarded with  
29  
30 a ISO27001/NEN7510 certificate to meet General Data Protection Regulation requirements  
31  
32 (19). Results will be published in open-access, peer-reviewed journals and disseminated by  
33  
34 presentations at scientific conferences. Data will be made available by requesting the  
35  
36 corresponding author.  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Patient and Public Involvement**

46  
47 Patients or the public were not involved in the design, or conduct, or reporting, or  
48  
49 dissemination plans of our research.  
50

### 51 52 53 54 **Competing interests**

55  
56 The authors declare no conflict of interest.  
57  
58  
59  
60

## Funding

This work was supported by Fonds Stichting Gezondheidszorg Spaarneland grant number 2021381 to J. Kooiman. This funding body was not involved in the development of the study design and will not be involved in conducting or reporting the results of the study.

## Acknowledgements

Not applicable.

## Author's contributions

JK, TL, WG, SG, FG, WO, EK, ES, and MM contributed to the overall design of the study and JK is the principal investigator of the study. All authors (JK, TL, WG, SG, FG, WO, EK, ES, MM, DK, MB, JD, SM, GM, HK, RJ, SA, RK, JJ, BR) read and approved the final version for submission.

## Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## Corresponding author

Correspondence to J. Kooiman ([j.kooiman@umcutrecht.nl](mailto:j.kooiman@umcutrecht.nl)).

**REFERENCES**

1. Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al. FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. *Int J Gynecol Obstet*. 2021;152(S1):3–57.
2. Pels A, Beune IM, van Wassenaer-Leemhuis AG, Limpens J, Ganzevoort W. Early-onset fetal growth restriction: A systematic review on mortality and morbidity. *Acta Obstet Gynecol Scand*. 2020;99(2):153–66.
3. Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: Cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). *Ultrasound Obstet Gynecol*. 2013;42(4):400–8.
4. Lees CC, Marlow N, Van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): A randomised trial. *Lancet*. 2015;385(9983):2162–72. doi:10.1016/S0140-6736(14)62049-3
5. Crovetto F, Crispi F, Scazzocchio E, Mercade I, Meler E, Figueras F, et al. First-trimester screening for early and late small-for-gestational-age neonates using maternal serum biochemistry, blood pressure and uterine artery Doppler. *Ultrasound Obstet Gynecol*. 2014;43(1):34–40.
6. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. *Am J Obstet Gynecol*. 2018;218(2):S745–61. doi:10.1016/j.ajog.2017.11.577
7. Zur RL, Kingdom JC, Parks WT, Hobson SR. The Placental Basis of Fetal Growth Restriction. *Obstet Gynecol Clin North Am*. 2020;47(1):81–98.

- 1  
2  
3 8. Maulik D. Fetal growth restriction: the etiology. *Clin Obstet Gynecol*. 2006 Jun;49(2):228–  
4 35.  
5  
6  
7
- 8 9. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating  
9 fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*.  
10 2020;2021(2).  
11  
12
- 13 10. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus  
14 Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal  
15 Outcomes. *JAMA*. 1995 Feb;273(5):413–8.  
16  
17
- 18 11. Melamed N, Shah J, Soraisham A, Yoon EW, Lee SK, Shah PS, et al. Association between  
19 antenatal corticosteroid administration-to-birth interval and outcomes of preterm  
20 neonates. *Obstet Gynecol*. 2015;125(6):1377–84.  
21  
22
- 23 12. Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, et al. Long-term  
24 outcomes after repeat doses of antenatal corticosteroids. *N Engl J Med*. 2007 Sep  
25 20;357(12):1190–8. doi:10.1056/NEJMoa071453  
26  
27
- 28 13. Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, et al. Monitoring of  
29 fetuses with intrauterine growth restriction: a longitudinal study. *Ultrasound Obstet  
30 Gynecol*. 2001 Dec;18(6):564–70. doi:10.1046/j.0960-7692.2001.00590.x  
31  
32
- 33 14. Committee on Practice Bulletins. ACOG Practice Bulletin - Fetal Growth Restriction.  
34 *Obstet Gynecol* [online]. 2021;137(2). [https://www.acog.org/clinical/clinical-](https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/02/fetal-growth-restriction)  
35 [guidance/practice-bulletin/articles/2021/02/fetal-growth-restriction](https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/02/fetal-growth-restriction) (accessed 11 June  
36 2022)  
37  
38
- 39 15. Royal College of Obstetricians and Gynaecologists. Green-Top Guideline 31: The  
40 Investigation and Management of the Small-for-Gestational-Age Fetus. RCOG Green-  
41 top Guidel [online]. 2014;(31):1–34.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [https://www.rcog.org.uk/globalassets/documents/guidelines/gtg\\_31.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdf) (accessed 11  
4  
5  
6 June 2022).
- 7  
8 16. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG  
9  
10 Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and  
11  
12 fetal growth restriction. *Ultrasound Obstet Gynecol.* 2020;56(2):298–312.
- 13  
14  
15 17. Stanislavsky A. Severe IUGR with critical dopplers [online]. [www.radiopaedia.org](http://www.radiopaedia.org)  
16  
17 (accessed 11 Aug 2022).
- 18  
19  
20 18. Wet medisch-wetenschappelijk onderzoek met mensen [online]. Wettenbank  
21  
22 Nederlandse Overheid. 2022  
23  
24 <https://wetten.overheid.nl/jci1.3:c:BWBR0009408&z=2022-07-01&g=2022-07-01>  
25  
26 (accessed 9 Nov 2022).
- 27  
28  
29  
30 19. General Data Protection Regulation (GDPR) [online]. 2018. <https://gdpr-info.eu/>  
31  
32 (accessed 9 Nov 2022).
- 33  
34  
35 20. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al.  
36  
37 Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound Obstet*  
38  
39 *Gynecol.* 2016;48(3):333–9.
- 40  
41  
42 21. Castor Electronic Data Capture (EDC) [online]. [https://www.castoredc.com/electronic-](https://www.castoredc.com/electronic-data-capture-system/)  
43  
44 [data-capture-system/](https://www.castoredc.com/electronic-data-capture-system/) (accessed 11 June 2022).
- 45  
46  
47 22. World Health Organization. Neonatal and Perinatal Mortality: country, regional and  
48  
49 global estimates. WHO Libr [online]. 2006.  
50  
51 [http://apps.who.int/iris/bitstream/handle/10665/43444/9241563206\\_eng.pdf;jsessionid](http://apps.who.int/iris/bitstream/handle/10665/43444/9241563206_eng.pdf;jsessionid=0C6676F5892402D63D4B6B1ECBE546C1?sequence=1)  
52  
53 [=0C6676F5892402D63D4B6B1ECBE546C1?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/43444/9241563206_eng.pdf;jsessionid=0C6676F5892402D63D4B6B1ECBE546C1?sequence=1) (accessed 11 June 2022).
- 54  
55  
56  
57 23. Healy P, Gordijn SJ, Ganzevoort W, Beune IM, Baschat A, Khalil A, et al. A Core Outcome  
58  
59 Set for the prevention and treatment of fetal GROwth restriction: deVelooping Endpoints:  
60



- 1  
2  
3 the COSGROVE study. *Am J Obstet Gynecol*. 2019;221(4):339.e1-339.e10.  
4  
5  
6 24. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al.  
7  
8 Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management  
9  
10 recommendations for international practice. *Hypertension*. 2018;72(1):24–43.  
11  
12  
13 25. Knight M. Eclampsia in the United Kingdom 2005. *BJOG An Int J Obstet Gynaecol*.  
14  
15 2007;114(9):1072–8.  
16  
17  
18 26. Hoftiezer L, Hof MHP, Dijks-Elsinga J, Hogeveen M, Hukkelhoven CWPM, van Lingen RA.  
19  
20 From population reference to national standard: new and improved birthweight charts.  
21  
22 *Am J Obstet Gynecol*. 2019 Apr;220(4):383.e1-383.e17.  
23  
24  
25 27. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med*. 2001  
26  
27 Jun;163(7):1723–9. doi:10.1164/ajrccm.163.7.2011060  
28  
29  
30 28. Neu J, Walker WA. Necrotizing enterocolitis. *N Engl J Med*. 2011 Jan 20;364(3):255–64.  
31  
32 doi:10.1056/NEJMra1005408  
33  
34  
35 29. Pellegrin S, Munoz FM, Padula M, Heath PT, Meller L, Top K, et al. Neonatal seizures:  
36  
37 Case definition & guidelines for data collection, analysis, and presentation of  
38  
39 immunization safety data. *Vaccine*. 2019;37(52):7596–609.  
40  
41 doi:10.1016/j.vaccine.2019.05.031  
42  
43  
44 30. Gopagondanahalli KR, Li J, Fahey MC, Hunt RW, Jenkin G, Miller SL, et al. Preterm  
45  
46 hypoxic-ischemic encephalopathy. *Front Pediatr*. 2016;4(OCT):1–10.  
47  
48  
49 31. De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The  
50  
51 Montreux definition of neonatal ARDS: biological and clinical background behind the  
52  
53 description of a new entity. *Lancet Respir Med*. 2017 Aug;5(8):657–66.  
54  
55  
56 32. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and  
57  
58 intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J*  
59  
60

- 1  
2  
3           Pediatr. 1978 Apr;92(4):529–34.  
4  
5  
6   33.   Martinez-Biarge M, Groenendaal F, Kersbergen KJ, Benders MJNL, Foti F, van Haastert  
7  
8       IC, et al. Neurodevelopmental Outcomes in Preterm Infants with White Matter Injury  
9  
10       Using a New MRI Classification. *Neonatology*. 2019;116(3):227–35.  
11  
12  
13   34.   Bayley N. The Bayley scales of infant and toddler development. San Antonio, TX:  
14  
15       Harcourt Assessment, Inc. 2006.  
16  
17  
18   35.   van Baar A, Steenis L, Verhoeven M, Hessen D. Bayley-III-NL; Technische handleiding.  
19  
20       Amsterdam, the Netherlands.: Pearson Assessment and Information B.V.; 2014.  
21  
22  
23   36.   Bax M, Goldstein M, Rosenbaun P, Leviton A, Paneth N, Dan B, et al. Proposed definition  
24  
25       and classification of cerebral palsy, April 2005. *Dev Med Child Neurol*. 2005;47(8):571.  
26  
27  
28   37.   Jenkins DA, Sperrin M, Martin GP, Peek N. Dynamic models to predict health outcomes:  
29  
30       current status and methodological challenges. *Diagnostic Progn Res*. 2018;2(1):1–9.  
31  
32  
33   38.   Fontein DBY, Klinten Grand M, Nortier JWR, Seynaeve C, Meershoek-Klein Kranenburg  
34  
35       E, Dirix LY, et al. Dynamic prediction in breast cancer: proving feasibility in clinical  
36  
37       practice using the TEAM trial. *Ann Oncol Off J Eur Soc Med Oncol*. 2015 Jun;26(6):1254–  
38  
39       62.  
40  
41  
42   39.   R Core Team (2021). R: A language and environment for statistical computing. [online].  
43  
44       R Foundation for Statistical Computing, Vienna, Austria. <https://www.r-project.org/>.  
45  
46       (accessed 9 Nov 2022).  
47  
48  
49   40.   Gulliford MC, Adams G, Ukoumunne OC, Latinovic R, Chinn S, Campbell MJ. Intraclass  
50  
51       correlation coefficient and outcome prevalence are associated in clustered binary data.  
52  
53       *J Clin Epidemiol*. 2005;58(3):246–51.  
54  
55  
56   41.   Hemming K, Girling AJ, Sitch AJ, Marsh J, Lilford RJ. Sample size calculations for cluster  
57  
58       randomised controlled trials with a fixed number of clusters. *BMC Med Res Methodol*.  
59  
60

- 1  
2  
3 2017;17(1):8.  
4  
5  
6 42. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the sample  
7  
8 size required for developing a clinical prediction model. *BMJ* [online].  
9  
10 2020;368(March):1–12. doi:10.1136/bmj.m441  
11  
12  
13 43. Norman M, Piedvache A, Børch K, Huusom LD, Bonamy AKE, Howell EA, et al. Association  
14  
15 of short antenatal corticosteroid administration-to-birth intervals with survival and  
16  
17 morbidity among very preterm infants results from the EPICE cohort. *JAMA Pediatr*.  
18  
19 2017;171(7):678–86.  
20  
21  
22  
23 44. Blankenship SA, Brown KE, Simon LE, Stout MJ, Tuuli MG. Antenatal corticosteroids in  
24  
25 preterm small-for-gestational age infants: a systematic review and meta-analysis. *Am J*  
26  
27 *Obstet Gynecol MFM*. 2020 Nov;2(4):100215. doi:10.1016/j.ajogmf.2020.100215  
28  
29  
30 45. Ting JY, Kingdom JC, Shah PS. Antenatal glucocorticoids, magnesium sulfate, and mode  
31  
32 of birth in preterm fetal small for gestational age. *Am J Obstet Gynecol* [Internet].  
33  
34 2018;218(2):S818–28. doi:10.1016/j.ajog.2017.12.227  
35  
36  
37 46. Walker D-M, Marlow N, Upstone L, Gross H, Hornbuckle J, Vail A, et al. The Growth  
38  
39 Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of  
40  
41 delivery in fetal growth restriction. *Am J Obstet Gynecol*. 2011 Jan;204(1):34.e1-9.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TITLES AND LEGENDS FIGURES


**Figure 1.** Timing strategies regarding antenatal CCS administration in early-onset FGR in the Netherlands

Abbreviations: CCS, corticosteroids; PI, pulsatility index; UA, umbilical artery. Reference image strategy "B": (17)

**Figure 2.** Study design and duration of follow-up

Abbreviations: FGR, fetal growth restriction; CCS, corticosteroids; PI, pulsatility index; UA, umbilical artery; AEDV, absent end-diastolic velocity; REDV, reversed end-diastolic velocity; FU, follow-up; CA, corrected age. Reference image strategy "B": (17)





**Supplementary file 1****COSGROVE: Core Outcome Set for FGR supplemented with other relevant endpoi**

Domain	Outcome
<b>Maternal</b>	Pre-eclampsia
	Eclampsia
	Maternal death
	Mode of birth
<b>Fetal</b>	Stillbirth/livebirth
<b>Neonatal</b>	Gestational age at birth
	Preterm birth
	Extremely preterm birth
	Birthweight
	Birthweight <10 <sup>th</sup> percentile
	Birthweight <3 <sup>rd</sup> percentile
	Need for mechanical ventilation
	Bronchopulmonary dysplasia, moderate and severe

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Necrotizing enterocolitis $\geq 2$ according to the Bell's stages
	Neonatal seizures
	Hypoxic-ischemic encephalopathy
	Neonatal death
	In-hospital death
	Respiratory distress syndrome
	Intraventricular hemorrhage
	Cystic periventricular leukomalacia
	Retinopathy of prematurity



1 2 3 4 5 6 7 8	Neonatal sepsis
9 10 11 12 13 14	Persistent pulmonary hypertension of the newborn
15 16	Duration of supplemental oxygen therapy during admission
17 18 19	Need for mechanical ventilation < 72 hours post-partum
20 21 22 23 24 25 26 27 28 29 30 31 32	<b>Childhood (Long-term follow-up)</b> Cognitive impairment (available for children born before 30 weeks gestational age, for children born after a longer pregnancy duration follow-up management varies between clinics)
33 34 35 36 37 38 39 40 41 42 43	Motor impairment (available for children born before 30 weeks gestational age, for children born after a longer pregnancy duration follow-up management varies between clinics)
44 45 46 47 48 49	Cerebral palsy
50 51	Hearing impairment
52 53 54 55 56 57 58 59 60	Visual impairment

**Terms with definitions (20)****Definition**

Gestational hypertension accompanied by one or more of the following new-onset conditions at or after 20 weeks' gestation:

1. Proteinuria;
2. Other maternal organ dysfunction, including: Acute kidney injury (creatinine  $\geq 90 \mu\text{mol/L}$ ;  $1 \text{ mg/dL}$ ); liver involvement (elevated transaminases e.g. ALT or AST  $> 40 \text{ IU/L}$ ) with or without right upper quadrant or epigastric abdominal pain); neurological complications (examples include eclampsia, altered mental status, blindness, stroke, clonus, severe headaches, persistent visual scotomata); haematological complications (thrombocytopenia – platelet count below  $150,000/\mu\text{L}$ , diffuse intravascular coagulation, hemolysis);
3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery Doppler wave form analysis, or stillbirth) (24)

Eclampsia refers to the occurrence of new-onset, generalized, tonic-clonic seizures or coma in a woman with preeclampsia (25)

Death of mother during pregnancy or the first six weeks after delivery (postpartum).

Defined as either vaginal or caesarean section.

Stillbirth: death of fetus ante- or intrapartum (22)

Livebirth: birth of a living neonate

Time in weeks and days

Delivery at  $< 37.0$  weeks gestation

Delivery at  $< 28.0$  weeks gestation

Weight at time of birth in grams (g)

Presence of birthweight below the 10<sup>th</sup> percentile according to Hoftiezer *et al.* (26)

Presence of birthweight below the 3<sup>rd</sup> percentile according to Hoftiezer *et al.* (26)

Need for intubation and mechanical ventilation to support gas exchange

Bronchopulmonary dysplasia is diagnosed if gestational age  $< 32$  weeks: at a postmenstrual age of 36 weeks,  $> 21\%$  oxygen has been administered cumulatively for 28 or more days (27)

- 1  
2 ○ Moderate: Need for <30% oxygen at 36  
3 weeks postmenstrual age  
4 ○ Severe: Need for ≥30% oxygen and/or  
5 positive pressure (positive pressure ventilation  
6 or continuous positive airway pressure) at 36  
7 weeks postmenstrual age

8  
9 Definitive medical necrotising enterocolitis:

- 10 • Abdominal distention with pneumatosis  
11 intestinalis, portal venous gas, or both.  
12 • Other radiographic signs such as fixed,  
13 dilated loops of intestine and ileus patterns are  
14 not pathognomonic but should be treated as  
15 such.

16  
17 Surgical necrotising enterocolitis:

- 18 • Free intraperitoneal air on abdominal  
19 radiograph after initial medical signs and  
20 symptoms.  
21 • Persistent ileus pattern, abdominal distension,  
22 and radiographs that show an absence of  
23 bowel gas, coupled with deteriorating clinical  
24 and laboratory values. (28)

25  
26  
27 Transient electrographic change in the brain  
28 due to an abnormal, excessive or synchronous  
29 neuronal activity either with the occurrence of  
30 clinical signs (electro-clinical) or without them  
31 (electrographic only) in preterm infants up to  
32 44 weeks of post menstrual age (29)

33  
34  
35 Clinical syndrome that results from a severe or  
36 prolonged hypoxic-ischemic episode before or  
37 during birth (30)

38  
39 Death of the neonate within 28 days after birth

40  
41 Death of the neonate until hospital-discharge

42  
43 Neonatal respiratory distress syndrome,  
44 characterized by extensive lung inflammation  
45 and surfactant catabolism leading to lung  
46 dysfunction, with need for surfactant (31)

47  
48  
49 Intraventricular hemorrhage grade 3 according  
50 to Papile *et al.*, venous infarction,  
51 posthemorrhagic ventricular dilatation needing  
52 treatment (32)

53  
54 Cystic periventricular leukomalacia  
55 characterized by diffuse injury of the white  
56 matter, which possibly leads to cerebral palsy  
57 (33)

58  
59 Retinopathy of prematurity with plus disease  
60 for which treatment is needed

- Early-onset: neonatal sepsis in the first 72 hours of age
- Late-onset: neonatal sepsis after the first 72 hours of age
- Clinical: based on clinical condition
- Culture-proven

Persistent pulmonary hypertension of the newborn occurs in case of persistent abnormally, elevated pulmonary vascular resistance after birth, leading to severe hypoxemia

Duration of supplemental oxygen therapy during admission (in days)

Need for intubation and mechanical strategies to support gas exchange within 72 hours after birth

A decreased ability of cognitive function using the Dutch Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III-NL) at a corrected age of 24 months. Severe disability will be defined as a Bayley Mental Development Index score more than 2SD below the mean score (i.e.  $\leq 70$ ). Moderate disability will be defined as a Bayley Mental Development Index score 1 to 2 SD below the mean score (i.e. 71-85) (34,35)

A decreased ability of fine and gross motor function using part of the Dutch Bayley Scales and Infant and Toddler Development, Third Edition (BSID-III-NL) at corrected age of 24 months. Severe disability will be defined as a score of more than 2 SD below the mean score (i.e.  $\leq 70$ ). Moderate disability will be defined as a score 1 to 2SD below the mean score (i.e. 71-85) (34,35)

A group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain (36)

A decreased ability of the auditory system requiring hearing aids or deafness

A decreased ability of the visual system requiring aids or blindness